Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Request metadata listed "Niagen Bioscience, Inc.", but the filing identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2016
Event: Entry into a Material Definitive Agreement (Business Financing Agreement) with Western Alliance Bank.
Key Financial Metrics and Debt Structure
- Facility Type: Formula-based revolving credit line.
- Maximum Principal Amount: $5,000,000.
- Interest Rate: Floating rate equal to the greater of 3.50% or the Prime Rate, plus 2.50 percentage points. An additional 5.00 percentage points applies during an event of default.
- Maturity Date: November 4, 2018.
- Collateral: Security interest in substantially all current and future personal property assets, including intellectual property.
- Upfront Costs: $25,000 facility fee and $900 due diligence fee paid upon execution.
- Advisory Fees: $100,000 consulting fee paid to Trump Securities LLC.
Material Changes and Covenants
The filing establishes a new debt obligation not previously disclosed in prior periods. The agreement includes specific financial covenants requiring the maintenance of:
- Quick ratio.
- EBDAS (Earnings Before Depreciation, Amortization, and Stock-based compensation).
- Minimum revenue thresholds.
Termination Provisions: If the agreement is terminated prior to November 4, 2017, a $50,000 termination fee is due, unless the Borrowers refinance with the same Lender.
Outlook, Risks, and Management Commentary
Use of Proceeds: The Borrowers intend to use the funds for working capital needs and general business requirements.
Risks and Contingencies:
- Default Risk: Failure to satisfy payment obligations, breach of covenants, or a material adverse change allows the Lender to declare all obligations due and payable.
- Asset Encumbrance: The company's intellectual property and personal property assets are now pledged as collateral.
- Refinancing Risk: A termination fee applies if the facility is closed within the first year without refinancing with the current lender.
Financial Statements: This 8-K does not contain audited financial statements, revenue, profit, or cash flow data. The filing text does not provide a clear value for current liquidity or existing debt levels outside of this new agreement.
Investor Verification Checklist
- Verify the company's current ability to meet the new quick ratio, EBDAS, and minimum revenue covenants.
- Confirm the status of the $100,000 advisory fee paid to Trump Securities LLC and its impact on cash reserves.
- Review the full text of the Agreement (to be filed as an exhibit to the 2016 Form 10-K) for detailed definitions of "Event of Default" and "Material Adverse Change."
- Assess the impact of the 2.50% spread over Prime/3.50% on future interest expense relative to current profitability.
- Monitor the company's cash flow to ensure it can service the debt and pay the annual facility fee and monthly collateral maintenance fee (0.05% of outstanding balance).